Increasingly clinical pharma and biotech organizations are deciding to commercialize on their own; just as Contract Research Organizations (CROs) transformed clinical trial operations, Contract Commercial Services are transforming commercial operations. Emerging service models offer new options for clinical organizations. In this podcast, Brent Herspiegel, CEO, and Santosh Naik, Partner, Herspiegel Consulting, share the considerations for pharma and biotech organizations when deciding on their commercial path and partner. How Contract Commercial Services can mitigate common launch risks, what we can learn from Herspiegel Consulting’s experience with 100+ pharma product launches.
FDA grants Ultomiris accelerated approval for primary immunoglobulin A nephropathy, a pharma funding roundup covers Alcon’s $550 million acquisition of Neurotech and AI Proteins’ collaboration with Astellas, and Incubate’s John Stanford on which therapeutic areas MFN deals might hit hardest.
Alcon is acquiring Neurotech Pharmaceuticals to add the only FDA-approved MacTel cell therapy to its retina portfolio, while AI Proteins has enters a collaboration with Astellas to design novel miniprotein therapeutics.
A new ICER and West Health report finds median drug launch prices climbed to $257,000, the FDA approves GSK’s Hibsago as the first functional-cure therapy for chronic hepatitis B, and CSL names Deborah Waterhouse as CEO and managing director.
Median net launch prices for new drugs climbed between 2022 and 2025 to $257,000, according to a new ICER and West Health report that also found persistent coverage and access barriers for patients.
